Australian (ASX) Stock Market Forum

IMM - Immutep Limited

Jump to new
1 year and 8 months since last post so thought a fresh chart is due. Nice breakout today filling the gap back in mid June, just might carry on.

1669617754328.png
 
themarketherald.com.au

Immutep (ASX:IMM) enters second collaboration with Pfizer and Merck KGaA for INSIGHT study

Immutep (ASX:IMM) has signed an agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical study in patients with urothelial cancer.
themarketherald.com.au themarketherald.com.au
Immutep (IMM) has signed an agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical study in patients with urothelial cancer.

The INSIGHT-005 trial will take place in Germany and will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti), in combination with avelumab (BAVENCIO) in up to 30 patients with metastatic urothelial cancer.

Live price chart: https://uk.advfn.com/p.php?pid=staticchart&s=ASX^IMM&p=5&t=1
 
IMM looks like got distraction with no posting for 12 months.
Lots of things happen to this stock.
CR and constant down fall . Financial institutions paid 38 cents and now you can buy ex rights at 28.5 cents today. Probably it will down further

1719537909087.png

1719537992070.png




1719538074632.png



 
Miner said:
IMM looks like got distraction with no posting for 12 months.
Lots of things happen to this stock.
CR and constant down fall . Financial institutions paid 38 cents and now you can buy ex rights at 28.5 cents today. Probably it will down further

View attachment 179468
View attachment 179469



View attachment 179470


Click to expand...
Having made so many losses on several stocks and loss opportunities by selling early, for IMM over last 10 days including today, I earned few hundreds by day trading for a change. It has a good intrinsic strength but market hype failed to recognise it. So couple of hundreds not bad for this shovel fit miner :)
 
Immutep's latest clinical results.

Key points:
  • Efti in combination with KEYTRUDA® (pembrolizumab) in first line head and neck squamous cell carcinoma (1L HNSCC) led to overall response rates that exceed KEYTRUDA monotherapy across all levels of PD-L1 expression
  • In the randomised, controlled Cohort A, the combination shows the strongest performance in patients with high PD-L1 expression (CPS >20) with an overall response rate (ORR) of 31.0% as compared to 18.5% for KEYTRUDA monotherapy
  • In patients with negative PD-L1 expression (CPS <1, Cohort B), a patient population with no effective chemotherapy-free options, the response rate has substantially improved from the preliminary 26.9% ORR reported in April and topline results with additional data has been accepted for oral presentation at an ESMO Virtual Plenary session on 11th July
  • Additional clinical data from TACTI-003 will be presented at a medical conference in H2 CY2024
  • Based on the positive topline results, the Company will discuss the path forward in 1L HNSCC with regulatory agencies
www.sharecafe.com.au

Immutep (ASX:IMM) TACTI-003 results, June 2024 - ShareCafe

Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific Officer Professor Frédéric Triebel, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep's latest clinical results.
www.sharecafe.com.au www.sharecafe.com.au
 
IMM will be my July tip
Trading View is SELL but technical analyst is a buy (hopefully will rise by 31 July )

1719735374832.png


1719735413150.png
 
Last edited:
Miner said:
IMM will be my July tip
Click to expand...
... you may be on to something... up 20 per cent
Screenshot_20240712-112041_CommSec.jpg

.
Immutep Reports Positive Results in First Line Head and Neck Squamous
Cell Carcinoma Patients with Negative PD-L1 Expression
• Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1
• High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment
• Durability of responses tracks well and over 50% of patients received treatment for at least six months
• Combination continues to have a favourable safety profile with no new safety signals observed
• Based on encouraging results and high unmet medical need, the path forward will be discussed with regulatory agencies
• Company hosted webcast today at 9am AEST
 
IMM - not visited for a couple of weeks and good to see the mercury on tipping line. DNH

1722236890106.png

The following is the game changer
1722236950837.png
 
Top